Workshop: Developing investor-ready valuations for pharma and medtech start-ups

AI Quick Summary

Join us for an exclusive hands-on valuation workshop tailored to start-ups in the pharma and medtech sectors. Hosted in partnership with EY at the Biopôle campus in Lausanne on April 7, 2025, this workshop will guide participants through the essentialelements of valuation and financial projections that every start-up needs for successful fundraising.Led by Pierre Corval, a valuation specialist with over 20 years of experience in life sciences, this interactive workshop will focus on valuation and financial projections issues in the pharma and medtech sectors, helping start-ups develop credible financial projections and valuations and build stronger, investor-ready pitches.You’ll gain insights and practical tools to help you win over investors, including:1. How valuation and financial projections attract investors.2. How to build solid financial projections with sector-specific data.3. How to use the risk-adjusted net present value (rNPV) method – a vital approach to start-up valuation in pharma and medtech.The session will end with a Q&A discussion, followed by the option for pre-scheduled one-on-one consultations to tackle your specific challenges. Don’t miss this opportunity to sharpen your fundraising strategy and valuation expertise!TARGET AUDIENCEKey decision-makers and professionals within pharma and medtech start-ups who are directly involved in strategic planning, fundraising and financial modelling, specifically:Founders and CEOs – to understand how valuation impacts your investor negotiations and business strategy.CFOs and Finance Managers – to gain insights on building accurate financial projectionsand applying valuation models, like risk-adjusted net present value (rNPV).Business Development and Strategy Leaders – to discover how valuation can drive partnerships, licensing deals and funding opportunities.R&D Managers and Chief Scientific Officers – to find out how your development timelines, costs and success probabilities impact the valuation of pipeline products.Investor Relations and Fundraising Specialists – to learn more effective ways to present valuation insights to potential investors and stakeholders.

Event Metadata

• Event Name: Workshop: Developing investor-ready valuations for pharma and medtech start-ups
• Date: 3/4/2025 3:33:58 PM
• Administrators:
  • Switzerland Innovation Digital

Event Description

Join us for an exclusive hands-on valuation workshop tailored to start-ups in the pharma and medtech sectors. Hosted in partnership with EY at the Biopôle campus in Lausanne on April 7, 2025, this workshop will guide participants through the essentialelements of valuation and financial projections that every start-up needs for successful fundraising.

Led by Pierre Corval, a valuation specialist with over 20 years of experience in life sciences, this interactive workshop will focus on valuation and financial projections issues in the pharma and medtech sectors, helping start-ups develop credible financial projections and valuations and build stronger, investor-ready pitches.

You’ll gain insights and practical tools to help you win over investors, including:

1. How valuation and financial projections attract investors.

2. How to build solid financial projections with sector-specific data.

3. How to use the risk-adjusted net present value (rNPV) method – a vital approach to start-up valuation in pharma and medtech.

The session will end with a Q&A discussion, followed by the option for pre-scheduled one-on-one consultations to tackle your specific challenges. Don’t miss this opportunity to sharpen your fundraising strategy and valuation expertise!

TARGET AUDIENCE

Key decision-makers and professionals within pharma and medtech start-ups who are directly involved in strategic planning, fundraising and financial modelling, specifically:

• Founders and CEOs – to understand how valuation impacts your investor negotiations and business strategy.
• CFOs and Finance Managers – to gain insights on building accurate financial projectionsand applying valuation models, like risk-adjusted net present value (rNPV).
• Business Development and Strategy Leaders – to discover how valuation can drive partnerships, licensing deals and funding opportunities.
• R&D Managers and Chief Scientific Officers – to find out how your development timelines, costs and success probabilities impact the valuation of pipeline products.
• Investor Relations and Fundraising Specialists – to learn more effective ways to present valuation insights to potential investors and stakeholders.